Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial
- 1 July 2014
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 109 (7) , 1055-1064
Abstract
Cost-effective guidance of therapeutic strategy in Crohn's disease patients with secondary infliximab (IFX) treatment failure may be achieved by serum IFX and anti-IFX antibody (Ab) measurements by radioimmunoassay (RIA). This study investigated implications of using other techniques for this purpose. This is a post hoc analysis of randomized clinical trial including 66 Crohn's disease patients with IFX failure in whom IFX and anti-IFX Ab measurements by RIA had been used for therapeutic guidance. Samples were additionally assessed by enzyme-linked immunosorbent assay (ELISA), homogeneous mobility shift assay (HMSA), and functional cell-based reporter gene assay (RGA). IFX detection was comparable between assays (82% RIA, 76% ELISA, 88% HMSA, and 74% RGA), and it correlated significantly (Pearson's r=0.91-0.97, P<0.0001). However, IFX concentrations varied systematically between all pair of assays except RIA-RGA. Anti-IFX Ab detection was variable (27% RIA, 9% ELISA, 33% HMSA, and 11% RGA), but correlated significantly (Pearson's r=0.77-0.96; P<0.0001). Anti-IFX Abs detected by RIA and HMSA were often from sera without drug-neutralizing activity (RGA). Assays agreed on classification of underlying mechanism for treatment failure in most cases (79-94%). The majority (74-88%) failed IFX owing to pharmacodynamic problems, or had noninflammatory pathophysiology for symptoms resembling relapse. Applied threshold for therapeutic vs. subtherapeutic IFX level influenced classifications. The four different assays did not differ in terms of the ability to predict response to interventions defined by the algorithm. Despite variable analytical properties, common assays result in similar classifications and interventions in patients with IFX treatment failure, and with comparable clinical outcomes. Implications are, however, profound for the minority classified differently.Keywords
This publication has 34 references indexed in Scilit:
- Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2013
- A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to InfliximabClinical Gastroenterology and Hepatology, 2013
- Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel diseaseInflammatory Bowel Diseases, 2012
- Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2012
- Guidelines for the management of inflammatory bowel disease in adultsGut, 2011
- Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-AnalysisAmerican Journal of Gastroenterology, 2011
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?American Journal of Gastroenterology, 2011
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current managementJournal of Crohn's and Colitis, 2010
- Management of Crohn's Disease in AdultsAmerican Journal of Gastroenterology, 2009
- Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodiesScandinavian Journal of Gastroenterology, 2009